Navigation Links
JDRF Announces Two Partnerships to Develop Stable, Pumpable Glucagon to Support Advanced Generation Artificial Pancreas Systems
Date:6/20/2013

NEW YORK, June 20, 2013 /PRNewswire-USNewswire/ -- JDRF announced today partnerships with both Xeris Pharmaceuticals, Inc., and LATITUDE Pharmaceuticals, Inc. (LPI), to support the development soluble glucagon formulations—an important step toward the advancement of future generation, fully automated and multi-hormonal artificial pancreas systems for people with type 1 diabetes (T1D).

First-generation artificial pancreas systems currently being tested in JDRF-supported outpatient clinical trials use technologies already available; they combine a continuous glucose monitor (CGM) with an insulin pump using computer software, to partially automate the right amount of insulin delivery at the right times for people with T1D.

"Studies have demonstrated the game-changing value of first generation artificial pancreas systems in improving blood-glucose control and alleviating some of the burdens of managing type 1 diabetes," said Sanjoy Dutta, Ph.D., JDRF's senior director of treat therapies. "Still, future generation artificial pancreas systems are expected to do even more. To become fully automated, closed loop systems, new technologies and drugs—including stable, pumpable glucagon—will be required in order to more closely and accurately mimic the functions of a healthy pancreas. Both near-term and long-term projects to advance the artificial pancreas are important research priorities for JDRF."

While first-generation artificial pancreas systems will deliver insulin, one of the aspects of future generations will be their ability to deliver multiple hormones, such as glucagon. Glucagon is a naturally occurring hormone that raises blood-sugar levels to prevent hypoglycemia (low blood sugar), but its regulation is impaired in people with T1D, for whom hypoglycemia can be dangerous. In a healthy pancreas, it complements the function of insulin to provide the natural fine-tuning o
'/>"/>

SOURCE JDRF
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Orexigen Therapeutics Announces Upcoming Clinical Data Presentations at American Diabetes Association Annual Scientific Meeting
2. Valeant Pharmaceuticals Announces Exercise Of Over-Allotment Option
3. Haemonetics Announces Next Steps in Manufacturing Transformation
4. Echo Therapeutics Announces Closing of Public Offering of Common Stock And Full Exercise of Over-Allotment Option by the Underwriter
5. BioCision Announces Two New U.S. Patents for Thermo-Conductive Products that Standardize Sample Handling in Laboratory Research
6. Chindex International, Inc. Announces Opening of Beijing United Family Rehabilitation Hospital
7. NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinsons Disease
8. Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes
9. Intercept Pharmaceuticals Announces Pricing of Public Offering of Common Stock
10. Specialty Coating Systems Announces New Antimicrobial Parylene Technology
11. Apama Medical Announces Issuance Of Patent For Low Profile Electrodes For Use On Balloons
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... , Spanien, September 2, 2014 /PRNewswire/ ... auf dem ESC-Kongress 2014 präsentierte GARFIELD-AF-Register ... und Behandlungsergebnisse von schlaganfallgefährdeten Patienten in ... Die Daten der ... einer innovativen und unabhängigen Forschungsinitiative zur ...
(Date:9/2/2014)... -- Donald Spector , a renowned celebrated entrepreneur ... a Wearable Biosensor, which will issue today, September 2, ... Mr. Spector holds some of the earliest patents in ... by New York College of Health Professions, which has ... intellectual properties.  New York College noted that the Wearable ...
(Date:9/2/2014)... , Sept. 2, 2014  Avanir Pharmaceuticals, Inc. (NASDAQ: ... an overview of the company at the Morgan Stanley Global ... , Presentation date: Tuesday September 9, 2014 , ... live webcast and 30-day archive of this presentation will be ... Pharmaceuticals, Inc. Avanir Pharmaceuticals, Inc. is a biopharmaceutical ...
Breaking Medicine Technology:Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 2Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 3Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 4Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 5Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 6Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 7Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 8Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 9Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 10Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 11Wearable Biosensor Patent, the Grandfather of Wearable Biosensor Transmission Patents, Granted to Donald Spector, One of the Most Prolific Living Inventors in the World 2Wearable Biosensor Patent, the Grandfather of Wearable Biosensor Transmission Patents, Granted to Donald Spector, One of the Most Prolific Living Inventors in the World 3Wearable Biosensor Patent, the Grandfather of Wearable Biosensor Transmission Patents, Granted to Donald Spector, One of the Most Prolific Living Inventors in the World 4Wearable Biosensor Patent, the Grandfather of Wearable Biosensor Transmission Patents, Granted to Donald Spector, One of the Most Prolific Living Inventors in the World 5
... historic open letter to the World Health Organization ... Drugs (CoMeD) , and the United Methodist Women are seeking ... vaccines.  Currently, the mercury-based preservative Thimerosal, which is 49% mercury ... much of the world, despite the fact that it is ...
... Texas, March 15, 2012  OxySure® Systems, Inc. (OTCBB: ... emergency oxygen solutions with its "oxygen from powder" ... a Supplier Agreement ("Agreement") with W.W. Grainger, Inc. ... (Logo:  http://photos.prnewswire.com/prnh/20120315/DA71084LOGO ) In terms ...
Cached Medicine Technology:Global Call for Mercury-free Vaccines Issued 2OxySure Systems Announces Supplier Agreement With Grainger 2OxySure Systems Announces Supplier Agreement With Grainger 3
(Date:9/2/2014)... Today, Therapy Changes released ... Me?” The guide outlines common questions an individual may ... to common types of groups an individual can attend. ... the interventions of the therapist, but also from observing ... members,” says Rochelle Perper, Ph.D. and founder of Therapy ...
(Date:9/2/2014)... Friendship Village of Schaumburg is proud ... a contemporary marketing presence and visually solidifies the ... Friendship Senior Options,” said Stephen A. Yenchek, president ... the logo, we are making sure that our ... their families.” , Friendship Village is a retirement ...
(Date:9/2/2014)... 2, 2014 (HealthDay News) -- Complications are rare ... reconstruction, a new study indicates. However, the ... associated with a slightly higher risk for certain ... included more than 18,000 breast cancer patients who ... mastectomy with breast reconstruction and were followed for ...
(Date:9/2/2014)... return to the emergency department within a few days of ... symptoms and have lost trust in other parts of the ... published online today in Annals of Emergency Medicine ... ). , "When asked why they did not ... symptoms were too severe to wait until their scheduled appointment ...
(Date:9/2/2014)... Sept. 2, 2014 (HealthDay News) -- Two new studies ... suggests that 6-year-olds who were breast-fed have a lower ... bottle-fed infants, while the other finds a similar trend ... the "many benefits of breast-feeding in the immediate newborn ... Hill Hospital in New York City. She was not ...
Breaking Medicine News(10 mins):Health News:Friendship Village of Schaumburg In Illinois Announces New Logo 2Health News:Complication Rates Low With Mastectomy, Breast Reconstruction: Study 2Health News:Discharged patients return to the ER because 'better safe than sorry' 2Health News:More Evidence Breast-Feeding Lowers Child's Risk of Infections, Allergies 2
... cancer-prevention gene in the response to drug treatment for childhood ... known as the guardian of the genome, is known for ... gene are associated with a high incidence of cancer due ... tumours. , In childhood cancers such as neuroblastoma, p53 mutations ...
... tuning out distractions can be learned , MONDAY, Nov. ... a person,s brain is organized, says a U.S. study that ... training. , All the participants were between the ages of ... than 10 years experience as a band or orchestra director ...
... FDA says clotting drug poses increased death risk, while company ... (HealthDay News) -- Bayer AG suspended worldwide sales of Trasylol, ... on Monday following a request from the U.S. Food and ... for safety reasons. , The FDA cannot identify a patient ...
... HONG KONG, Nov. 5 Mass Financial Corp. ... a lawsuit in the Supreme Court of,British Columbia, ... for breach of contract and contract interference. In ... Michael Smith, President of MASS said the ...
... Inc. (Nasdaq: ALTH ) today reported financial results for ... 30, 2007, the,Company reported a net loss of $9.3 million, ... $8.1 million, or ($0.15) per share, for the third,quarter of ... Company,reported a net loss of $28.1 million, or ($0.43) per ...
... 5 Hooper Holmes,Inc. (AMEX: HH ) announced ... after-market on Thursday, November 8, 2007. The Company,will host ... 11:00 a.m.,Eastern Time. To participate in the third ... Hooper Holmes. A live web cast,will be hosted on ...
Cached Medicine News:Health News:Training, Experience Can Change How Brains Work 2Health News:Trasylol Pulled From Worldwide Market 2Health News:Trasylol Pulled From Worldwide Market 3Health News:Trasylol Pulled From Worldwide Market 4Health News:Mass Financial Corp. Launches Lawsuit Against Elekta AB, Seeks Substantial Damages 2Health News:Allos Therapeutics Reports Third Quarter 2007 Financial Results 2Health News:Allos Therapeutics Reports Third Quarter 2007 Financial Results 3Health News:Allos Therapeutics Reports Third Quarter 2007 Financial Results 4Health News:Allos Therapeutics Reports Third Quarter 2007 Financial Results 5Health News:Allos Therapeutics Reports Third Quarter 2007 Financial Results 6Health News:Allos Therapeutics Reports Third Quarter 2007 Financial Results 7Health News:Hooper Holmes Announces Third Quarter Earnings Release Date and Conference Call Information 2
Battery operated single speed motorized handpiece, tip cover, supplied with 0.5 mm tungsten burr (E0815 0.5) and one battery size "AA"....
5.5 mm disk shape burr. Diamond coated tip. Use with E0824 B handle....
Taper with blunt tip. Stainless steel. Round knurled handle with polished finish. Taper : Long 32 mm. Overall length: 3.9 inches. Most popular size or model....
One end with needle point and other end with medium taper. Stainless steel. Round knurled handle with polished finish. Overall length: 5.7 inches....
Medicine Products: